New Century buy expands Tasly's cardiovascular portfolio
This article was originally published in Scrip
Executive Summary
The Chinese manufacturer of traditional medicines, Tianjin Tasly, and a subsidiary have jointly paid around CNY200m ($31.5m) to acquire 60% of Henan New Century Pharmaceutical, a domestic manufacturer of plant-based medicines best known for a stroke treatment.